Serum prolidase I activity and some bone metabolic markers in patients with breast cancer: in relation to menopausal status
Autor: | Zeynep Özbek Kır, Murat Koser, Yıldız Öner Iyidoğan, Seden Kucucuk, Sembol Türkmen, Pernur Öner, Hikmet Koçak |
---|---|
Rok vydání: | 2003 |
Předmět: |
Adult
Oncology Dipeptidases medicine.medical_specialty Deoxypyridinoline Urinary system Osteocalcin Clinical Biochemistry Bone Neoplasms Breast Neoplasms Bone remodeling Metastasis chemistry.chemical_compound Breast cancer Predictive Value of Tests Internal medicine medicine Humans Amino Acids business.industry Cancer General Medicine Middle Aged medicine.disease Menopause Endocrinology chemistry Predictive value of tests Calcium Female business Biomarkers |
Zdroj: | Clinical Biochemistry. 36:289-294 |
ISSN: | 0009-9120 |
DOI: | 10.1016/s0009-9120(03)00028-6 |
Popis: | Objectives The purpose of this study was to investigate the diagnostic value of some osteoblastic/osteoclastic biochemical markers and serum prolidase I activity in breast cancer (BC). Design and methods Serum bone gla protein (BGP), prolidase I activity, urinary deoxypyridinoline (Dpy) and calcium excretions were measured, in metastatic and nonmetastatic BC patients, and in 52 healthy women. Results In patients with metastases, bone turnover markers were found to be significantly higher than those in the control group and in patients without metastases. Serum prolidase activity in patients with and without metastases was also significantly higher than those in the control group, but there was no difference between the two patient groups. Conclusions Bone turnover has been suggested to be accelerated in BC patients with the more pronounced osteolytic activation, especially in metastatic state. Serum prolidase in premenopausal period appears to be valuable in discriminating cancer patients from controls. BGP and to a lesser degree of Dpy, may be useful markers for predicting the metastatic bone involvement, as well as for the more cost effective management of BC patients and monitoring the effects of antiresorptive therapy of malignant osteolysis before any metastasis could be detected by other invasive techniques. |
Databáze: | OpenAIRE |
Externí odkaz: |